Marksans Pharma Limited, a active public limited company, was established on 16 April 1992 in Mumbai, Maharashtra, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: L24110MH1992PLC066364. Registered under ROC Roc Mumbai. it is listed on BSE: 524404 and NSE: MARKSANS. It has an authorized capital of ₹69.00 Cr and a paid-up capital of ₹45.32 Cr.
Formerly known as Tasc Pharmaceuticals Limited, Tasc Industries (India) Limited. It upholds a compliant status. In 2023, it reported revenue of ₹715.69 Cr and a net worth of ₹1,111.32 Cr. Employing 95 professional, Its leadership includes Varddhman Vikramaditya Jain (Whole-Time Director), Abhinna Mohanty Sundar (Director), Sunny Sharma (Director). Past directors included Vinay Gopal Nayak, Kim Tan Sze, Varddhman Vikramaditya Jain. It holds ₹226.00 Cr open charges and ₹337.16 Cr settled loans. Its latest AGM occurred on 08 August 2025, with the balance sheet filed on 31 March 2025. It is based at 11Th Floor, Grandeur, Veera Desai Extension Road Oshiwara, Andheri (W), Mumbai, Maharashtra, 400053.
L24110MH1992PLC066364
066364
16 April 1992
₹69.00 Cr
₹45.32 Cr
Roc Mumbai
Listed (BSE: 524404, NSE: MARKSANS)
Active
Explore comprehensive insights into Marksans Pharma Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Varddhman Vikramaditya Jain | Whole-Time Director | 24 Jan 2019 | Current |
| Abhinna Mohanty Sundar | Director | 11 Jul 2019 | Current |
| Sunny Sharma | Director | 11 Aug 2021 | Current |
| Shailaja Vardhan | Director | 30 May 2023 | Current |
| Sandra Saldanha | Whole-Time Director | 25 Sep 2014 | Current |
| Mark Saldanha | Managing Director | 06 Oct 2015 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 29 Sep 2016 | Past |
| Pramod Abcsdd | Director | 25 Sep 2009 | Past |
| Pramod Abcsdd | Director Appointed In Casual Vacancy | 29 Sep 2020 | Past |
| Pramod Abcsdd | Additional Director | 23 Sep 2021 | Past |
| Pramod Abcsdd | Additional Director | 26 Sep 2019 | Past |
| Pramod Abcsdd | Director Appointed In Casual Vacancy | 26 Sep 2013 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Marksans Pharma Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.16% increase. The company also saw a slight decrease in profitability, with a 1.08% decrease in profit. The company's net worth Soared by an impressive increase of 41.63%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Marksans Pharma had a promoter holding of 43.85% and a public holding of 56.15%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹2,260,000,000.00
₹3,371,598,900.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Feb 2006 | State Bank Of India | ₹226.00 Cr | Open |
| 07 Sep 2017 | State Bank Of India | ₹66.80 Cr | Satisfied |
| 23 Jun 2015 | State Bank Of India | ₹44.41 Cr | Satisfied |
| 23 Dec 2013 | Bank Of India | ₹4.00 Cr | Satisfied |
| 13 Aug 2010 | Bank Of India | ₹6.00 Cr | Satisfied |
Explore comprehensive loan charge details -
Marksans Pharma has a workforce of 95 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Marksans Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Marksans Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Marksans Pharma Limited last Annual general meeting of members was held on 08 Aug 2025 as per latest MCA records. was recorded as a recent event.
The activity Srinivas Mishra was appointed as a Additional Director was appointed as a Additional Director on 01 Apr 2025 & has been associated with this company since 7 months 30 days . was completed.
Marksans Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was recorded as a recent event.
The activity A charge with State Bank Of India of Rs. 226.00 Cr registered on 07 Feb 2006 with Charge ID 80034914 was modified on 03 Feb 2025. was completed.
The activity Shailaja Vardhan was appointed as a Director was appointed as a Director on 30 May 2023 & has been associated with this company since 2 years 6 months . was completed.
A charge registered on 07 Sep 2017 via Charge ID 100125187 with State Bank Of India was fully satisfied on 29 Oct 2021. was recorded as a recent event.
The Mumbai-headquartered firm is engaged in research, manufacturing and marketing of generic pharmaceutical formulations in the global markets. .
The United States Food and Drug Administration (USFDA) has concluded inspection of company's Goa plant, Marksans Pharma said in a filing to BSE. .
The reason for recall is " various strengths of Ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies," latest enforcement report of the US health regulator said..
The CIN of Marksans Pharma Limited is L24110MH1992PLC066364.
Marksans Pharma Limited is headquartered at 11Th Floor, Grandeur, Veera Desai Extension Road Oshiwara, Andheri (W), Mumbai, Maharashtra, 400053.
Marksans Pharma Limited was incorporated on 16 April 1992.
The current directors of Marksans Pharma Limited are
The primary industry of Marksans Pharma Limited is Manufacturing.
Marksans Pharma Limited is listed. It is listed on BSE: 524404 and NSE: MARKSANS.
The authorized capital of Marksans Pharma Limited is ₹69.00 Cr, and the paid-up capital is ₹45.32 Cr.
The compliance status of Marksans Pharma Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX